Results 71 to 80 of about 6,305 (206)

Shelf-Life of e-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugates, Precursors for At-211 Labeling of Antibodies

, 2015
Astatine-211 is possibly the most promising radionuclide for targeted alpha-particle therapy when it comes to the treatment of occult disseminated cancer.
Lindegren, Sture, Jensen, H.,, Jensen, H., Albertsson, Per,, Aneheim, Emma, Holgersson, Stellan,, Aneheim, Emma,, Holgersson, Stellan, Albertsson, Per, Halleröd, Jenny,, Halleröd, Jenny, Haller\uf6d, Jenny, Lindegren, Sture,   +12 more
core   +1 more source

Selection of an Anti-CD20, Single-Chain Antibody by Phage ELISA on Fixed Cells

BioTechniques, 1999
Cloning the correct genes that code for antibody-variable domains from hybridomas is often complicated by the presence of several immunoglobulin transcripts, some of them arising from a myeloma cell line.
Stefanie Schmidt, Michael Braunagel, Timo Kürschner, Melvyn Little   +3 more
doaj   +1 more source

Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67

The Journal of Pathology, Volume 267, Issue 1, Page 69-78, September 2025.
Abstract Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target for melanoma immunotherapy, but its expression in benign melanocytic lesions and its diagnostic value remain unexplored. This study assessed CSPG4 expression in benign nevi (BN), dysplastic nevi (DN), and superficial spreading melanomas (SSM), comparing it with PRAME ...
Elias A T Koch, Christina Seidel, Ramona Erber, Michael Erdmann, Markus V Heppt, Stefan Schliep, Carola Berking, Jan Dörrie, Niels Schaft   +8 more
wiley   +1 more source

Preparation and examination of 177Lu- and 90Y-labeled immunoconjugates of Trastuzumab [PDF]

, 2019
Trastuzumab is a monoclonal antibody for treatment of HER2 positive breast cancer. Labelled antibody with lutetium-177 and yttrium-90 has been investigated as potential radiopharmaceutical agent for use in radioimmunotherapy.
Janevik-Ivanovska, Emilija, Vanjes Duric, Sanja, Mirkovic, Marija, Radovic, Magdalena, Jankovic, Drina, Dzodic, Predrag, Arev, Marija, Makreski, Petre   +7 more
core   +2 more sources

Author Correction: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Nature Communications, 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Anna Galstyan, Janet L. Markman, Ekaterina S. Shatalova, Antonella Chiechi, Alan J. Korman, Rameshwar Patil, Dmytro Klymyshyn, Warren G. Tourtellotte, Liron L. Israel, Oliver Braubach, Vladimir A. Ljubimov, Leila A. Mashouf, Arshia Ramesh, Zachary B. Grodzinski, Manuel L. Penichet, Keith L. Black, Eggehard Holler, Tao Sun, Hui Ding, Alexander V. Ljubimov, Julia Y. Ljubimova   +20 more
doaj   +1 more source

Immunoconjugates of carbon nanostructures

, 2006
For the first time, carbon nanostructures have been designed and synthesized to form immunoconjugates with monoclonal antibodies (mAb) for use in cell-targeted cancer diagnosis and therapy.
Ashcroft, Jared Mark
core  

Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders

, 2011
The year 1997 was pivotal in lymphoma research, as it was the year that the US FDA approved rituximab. Rituximab significantly altered clinical management and outcomes of patients with B-cell malignancies.
Myron S Czuczman, Lyudmyla Derby
core   +1 more source

Soluble CD4 and low molecular weight CD4-mimetic compounds sensitize cells to be killed by anti-HIV cytotoxic immunoconjugates

, 2023
The reservoir of HIV-infected cells that persist in the face of effective anti-retroviral therapy (ART) is the barrier to curing HIV infection. These long-lived CD4+ cells carry a functional provirus that can become activated upon immune stimulation ...
Cole, Frances M., Chen, Hung-Ching, Peters, Tami, Pincus, Seth H., Watt, Connie, Smith III, Amos B., Ober, Kelli, Stackhouse, Megan   +7 more
core   +1 more source

CD74 in kidney disease

Frontiers in Immunology, 2015
CD74 (invariant MHC class II) regulates protein trafficking and is a receptor for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT/MIF-2).
Lara eValiño-Rivas, Ciro eBaeza-Bermejillo, Laura eGonzalez-Lafuente, Ana eSanz, Alberto eOrtiz, Alberto eOrtiz, Alberto eOrtiz, Maria D Sanchez-Niño   +7 more
doaj   +1 more source

Preparation and in vitro cytotoxic evaluation of taxol immunoconjugates

, 2007
463-468The taxol (paclitaxel) immunoconjugates prepared by derivatizing the taxol at two positions and linking the Mab CIBCNSH3 against EGF receptors were tested for in vitro cytotoxicity.
Ganesh, S, Rao, Y Madhusudan, Kishan, V, Baheti, V, Saisivam, S, Prabhakar, K   +5 more
core